Halyard Health Company Profile (NYSE:HYH)

Halyard Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HYH."

Halyard Health, Inc. (NYSE:HYH) announced its earnings results on Tuesday, May, 2nd. The company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.05. The firm had revenue of $395.60 million for the quarter, compared to analyst estimates of $391.56 million. Halyard Health had a net margin of 2.40% and a return on equity of 8.16%. The company's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.53 EPS. View Halyard Health's Earnings History.

Halyard Health updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided EPS guidance of $1.70 - $2.00 for the period, compared to the Thomson Reuters consensus estimate of $1.84.

4 brokers have issued 12 month target prices for Halyard Health's stock. Their forecasts range from $35.00 to $45.00. On average, they expect Halyard Health's stock price to reach $39.33 in the next year. View Analyst Ratings for Halyard Health.

Here are some recent quotes from research analysts about Halyard Health stock:

• 1. According to Zacks Investment Research, "Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. " (7/12/2017)
• 2. Stifel Nicolaus analysts commented, "HYH closed 2016 with its fourth consecutive quarter of sales and EPS upside relative to both Consensus and management guidance. After a more difficult than expected first-year (2015) post-spin, in 2016, the company's transformation took clearer shape and was highlighted by: accretive M&A, a positive mix shift to the more profitable Medical Device franchise (38% of sales; 64% of operating profit), successful re-negotiations of material GPO contracts, significant organic cost-savings and stepped-up investments, all with significantly improved cash flow generation ($100M+ guide vs. $160M actual). We continue to believe HYH has further price appreciation potential ahead as '2016-like' thematic drivers continue playing out over the next 12-24 months. Still, we acknowledge that HYH shares (+56% TTM vs. S&P500: +23%) trading at 20x 2018E EPS (vs. large cap ~18x) could "pause" here as the stock absorbs the recent out-performance and the next wave of potentially positive catalysts becomes more visible. Yet to be realized sales, margin, and EPS-enhancing catalysts could include: IT cost savings, better S&IP pricing, more normal nitrile pricing and most important, further accretive M&A opportunities. Company-specific 2017 headwinds could include: more intense commodity price inflation, stepped up On-Q competition, and still uncertain macro tax-related legislation. For us, the bottom line is that HYH remains a positive long-term transformation story that is still in 'early innings' with significant opportunity both organically and through acquisitions to leverage earnings. We rate HYH Buy and raise our TP to $45 (from $38)." (2/28/2017)

Some companies that are related to Halyard Health include ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), AtriCure (ATRC), Intersect ENT (XENT), Meridian Bioscience (VIVO), CryoLife (CRY) and Landauer (LDR).

Halyard Health's management team includes the folowing people:

• Robert E. Abernathy, Chairman of the Board
• Joseph F. Woody, Chief Executive Officer, Director
• Steven E. Voskuil, Chief Financial Officer, Senior Vice President
• Christopher M. Lowery, Chief Operating Officer, Senior Vice President
• Rhonda D. Gibby, Chief Human Resource Officer, Senior Vice President
• John W. Wesley, Senior Vice President, General Counsel
• Christopher G. Isenberg, Senior Vice President - Global Supply Chain and Procurement
• Warren J. Machan, Senior Vice President - Business Strategy
• Ronald W. Dollens, Lead Independent Director
• Gary D. Blackford, Independent Director

Halyard Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Confluence Investment Management LLC (0.21%), Malaga Cove Capital LLC (0.12%), Aperio Group LLC (0.06%), Legacy Private Trust Co. (0.06%), Meyer Handelman Co. (0.06%) and Adams Diversified Equity Fund Inc. (0.05%). Company insiders that own Halyard Health stock include Robert E Abernathy and Steven E Voskuil. View Institutional Ownership Trends for Halyard Health.

Halyard Health's stock was sold by a variety of institutional investors in the last quarter, including Meyer Handelman Co., Legacy Private Trust Co., Adams Diversified Equity Fund Inc., Bank of Montreal Can, Meeder Asset Management Inc., US Bancorp DE and CENTRAL TRUST Co. View Insider Buying and Selling for Halyard Health.

Halyard Health's stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Aperio Group LLC, Nisa Investment Advisors LLC, Oregon Public Employees Retirement Fund, Alpha Windward LLC, Malaga Cove Capital LLC, LS Investment Advisors LLC and Louisiana State Employees Retirement System. Company insiders that have bought Halyard Health stock in the last two years include Robert E Abernathy and Steven E Voskuil. View Insider Buying and Selling for Halyard Health.

Shares of Halyard Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Halyard Health stock can currently be purchased for approximately $39.44.